SCHEMBL20522286

SCHEMBL20522286

COC(=O)CCCNc1ccccc1-c1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
QPCT Q16769 2/20 0.50
SLC6A4 P31645 1/20 0.49
SLC6A3 Q01959 1/20 0.49
CHRM3 P20309 5/20 0.44
STAT3 P40763 1/20 0.43
ALDH1A1 P00352 3/20 0.41
LMNA P02545 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPK13 O15264 1/20 0.40
MAPK12 P53778 1/20 0.40
MAPK11 Q15759 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrazine SCHEMBL28348678 0.83 QPCT (0.50) QPCTSLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL20522374 0.82 QPCT (0.49) QPCTSLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL30610435 0.82 QPCT (0.49) QPCTSLC6A4SLC6A3ALDH1A1LMNA
SCHEMBL22712395 0.81 QPCT (0.57) QPCTALDH1A1LMNAKDM4EGAA
SCHEMBL29926617 0.81 QPCT (0.57) QPCTALDH1A1LMNAKDM4EGAA
SCHEMBL29035072 0.81 QPCT (0.47) QPCTSLC6A4SLC6A3CHRM3STAT3
SCHEMBL6971190 0.80 ALDH1A1 (0.46) ALDH1A1LMNASMN1; SMN2KDM4EGAA
SCHEMBL11320449 0.77 TOP2A (0.56) ALDH1A1KDM4EMAPT
SCHEMBL20522389 0.77 QPCT (0.53) QPCTSLC6A4SLC6A3CHRM3STAT3
SCHEMBL31756005 0.77 QPCT (0.53) QPCTSLC6A4SLC6A3CHRM3STAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12384772-B2 Inhibitors VIVORYON THERAPEUTICS N.V. (DE) 2025-08-12 US disclosed
CN-117024352-A Novel inhibitors 维沃里翁治疗股份有限公司 2023-11-10 CN disclosed
CN-110719910-B Novel inhibitors 维沃里翁治疗股份有限公司 2023-07-21 CN disclosed
US-20220274977-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2022-09-01 US disclosed
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 US disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 EP disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT QPCT 3/4885SLC6A4 1579/4885SLC6A3 1182/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS QPCT 2/4885SLC6A4 1427/4885SLC6A3 986/4885
US-12384772-B2 Inhibitors GLS, QPCT, GLS2 QPCT 2/4885SLC6A4 1271/4885SLC6A3 466/4885
US-20220274977-A1 NOVEL INHIBITORS GLUL, GLS, QPCT QPCT 3/4885SLC6A4 1629/4885SLC6A3 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.